Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2019 07:00 ET | Source: Kamada Ltd.

Kamada to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6

REHOVOT, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...
May 14, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Reports Financial Results for First Quarter of 2019

Total Revenues for Q1 2019 were $26.8 Million, up 54% over Q1 2018Q1 2019 Proprietary Products Revenues up 67% Year-over-Year Gross Profit for Q1 2019 Grew 59% Year-over-YearAdjusted EBITDA was $6.6...
May 07, 2019 07:00 ET | Source: Kamada Ltd.

Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14

REHOVOT, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the...
April 16, 2019 07:00 ET | Source: Kamada Ltd.

Kamada announces FDA acceptance of Inhaled AAT program path forward

REHOVOT, Israel, April 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food and...
March 14, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Awarded the Israeli Outstanding Exporter Award for 2017

Company received the award from the Israeli Minister of Economy and Industry for its growing export revenues For fiscal 2017, Kamada's total revenues were $102.8 Million, an increase of more than 33%...
February 27, 2019 09:00 ET | Source: Kamada Ltd.

Kamada Files Annual Report for the Year Ended December 31, 2018

REHOVOT, Israel, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it has filed its annual report on Form...
February 12, 2019 06:00 ET | Source: Kamada Ltd.

Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018

Total Revenues for Fiscal 2018 were $114.5 Million, up 11% Over Fiscal 2017; In-line with Recently Provided 2018 Expected Revenues of $113 Million and $115 Million Full-Year Proprietary Products...
February 06, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48...
February 05, 2019 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12

REHOVOT, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...
January 30, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development

REHOVOT, Israel, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Michal Ayalon, Ph.D., as...